Boehringer Ingelheim caps inhaler out-of-pocket costs at $35 after political pressure
After Senate Democrats on the health committee pressed inhaler manufacturers on their high US prices earlier this year, Boehringer Ingelheim said Thursday that it would cap out-of-pocket costs at $35 per month for all of its inhalers.
The lower out-of-pocket costs, however, won’t begin until June, and government restrictions exclude people enrolled in federal insurance programs from copay support, according to BI.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
